# Clinical Inbox Phase A — independent PRE-CODE R2 P1/P2 closure PASS receipt

**Date:** 2026-10-24 (Asia/Nicosia). **Type:** Product Owner-supplied independent read-only review handback; durable evidence registration, **NOT an author-performed independent review**.

**Verdict received verbatim:** `PASS | COMPLETE_FOR_DECLARED_SCOPE | P0:P1:P2=0:0:0`.

**Disposition:** P1 — **CLOSED**; P2 — **CLOSED**; newly affected material risk — **NONE**.

**Target:** [DRAFT PR #208](https://github.com/athpapachr-cmd/osteoporosis/pull/208), corrected design `7a79ec44ae010cfc68f87c39b6f2bc301fa3cc2c`; historical review checkpoint `5c88d39ca188646276ae2628894dfcd8366ba031`; GitHub `main` at review `32a87ec8757b21b64dd8837e362810b5a2b9b510`. Original PRE-CODE review was BLOCK (P0:P1:P2=0:1:1); this handback closes those two defects, with original 2026-10-08 Q1–Q6 two-entrance R2 PASS reused unchanged.

**Source blob P1/P2:** [corrected Phase A contract](https://github.com/athpapachr-cmd/osteoporosis/blob/7a79ec44ae010cfc68f87c39b6f2bc301fa3cc2c/cockpit/CLINICAL_INBOX_PHASE_A_MULTI_ACCOUNT_CONTRACT_2026-10-23.md) blob `79696ff1972c12d2156c9c7bc0741db798cf11ad`, §3A lines 57–67.
**Affected two-entry design:** [source](https://github.com/athpapachr-cmd/osteoporosis/blob/7a79ec44ae010cfc68f87c39b6f2bc301fa3cc2c/cockpit/VISIT_BRIEF_CLINICAL_INBOX_DESIGN_2026-10-07.md) blob `9f24c93d7065f858e20d922f5f706393fce40732`.

## P1 — CLOSED: logical identity and source revisions

- `logical_source_item_key` is stable independently of content/version, while `source_receipt_version_key` identifies an immutable source revision, ensuring exact replay.
- One verified correction retains the original `item_id` and atomically transitions to `needs_re_review`, invalidating stale candidates, dispositions and **unsent** approvals.
- Atomic CAS/expected version and 409 reject concurrent stale clinician approvals.
- Already submitted communications preserve historical evidence and unknown outcomes; no automatic re-send.

## P2 — CLOSED: provider identity and mixed-patient isolation

- IMAP identity is account + folder scope + UIDVALIDITY + UID; moves/resets and ambiguous correlation remain incomplete/needs-reconciliation.
- Microsoft Graph immutable ID is deferred to independent adapter/provider qualification, not assumed valid at Phase A.
- Mixed-subject document or PDF remains **Inbox-only** unless evidence-backed subject segmentation and clinician-verified patient identity separately authorize patient-specific exposure. No whole-PDF chart/Visit Brief leak, automatic fanout or contact.

## Affected cumulative consistency and exact next lawful step

The independent handback reported corrected two-entry design and Phase A contract consistent with `CURRENT_OPERATIONAL.md`, `cockpit/CURRENT.md`, `cockpit/PRODUCT_CONSTITUTION.md`, `CLINICAL_EXCELLENCE_PLAN.md`, `TODO.md`, and existing Clinical Excellence / Reception / Pending owners. No re-review of Q1–Q6 needed.

**Separate implementation authorization:** In this conversation the Product Owner expressly instructed `Προχωράμε σε καταγραφή και αν pass υλοποιηση`. This original conditional permission is now satisfied by the supplied PASS. Only **Phase A synthetic/manual code and test implementation** is authorized in a draft branch, with one later independent post-code R2 fidelity review before release.

**Still NOT authorized:** schema migration/grants/role changes in production; retention activation for real clinical patients; patient PHI; Gmail, iCloud Mail, Hotmail/Outlook tokens or live emails; Reception/Zadarma sends; merge or deployment. Any synthetic/manual prototype must not claim persistent real clinic records or live mailbox coverage.

The earlier [administrative outcome-pending receipt](CLINICAL_INBOX_PHASE_A_MULTI_ACCOUNT_PRECODE_R2_CLOSURE_OUTCOME_PENDING_2026-10-24.md) is superseded as to the verdict; its historical record that the handback was initially unavailable remains true. **R2 design review chain CLOSED.**
